KAREN FONG: Open Payments
NPI 1528789047 · DUBLIN, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,010 in 36 payments from 17 companies in 2025. Trend: 2023 $0 · 2024 $565 · 2025 $2,010
Food & beverage: $1,910Education: $100
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $352 |
| GlaxoSmithKline, LLC. | 5 | $301 |
| Lilly USA, LLC | 2 | $155 |
| Arcutis Biotherapeutics, Inc. | 1 | $137 |
| JAZZ PHARMACEUTICALS INC. | 2 | $136 |
| Teva Pharmaceuticals USA, Inc. | 1 | $132 |
| Madrigal Pharmaceuticals | 1 | $130 |
| ViiV Healthcare Company | 1 | $122 |
| Amgen Inc. | 4 | $116 |
| Organon LLC | 1 | $114 |
Products named: TEZSPIRE, NUCALA, BREZTRI, Zoryve, XYWAV, REZDIFFRA, ZEPBOUND, APRETUDE.
Industry payments across CA — which companies pay providers there.
